COLUMBIA-ADARC-CORNELL AIDS CLINICAL TRIALS UNIT

描述（改编自应用程序的摘要）： 本申请是在成人艾滋病临床部位内形成的 临床试验组（AACTG），将有效执行设计的研究 提高对艾滋病的认识和治疗。 这个网站，A 哥伦比亚长老会医疗中心（哥伦比亚）与亚伦 钻石艾滋病研究中心（ADARC）将被指定为哥伦比亚-ADARC 艾滋病临床试验股。 哥伦比亚将作为主要单位，ADARC作为 这两个机构合作的分单位已经在科学上 与最近获得的艾滋病研究中心（CFAR）赠款有关。 的 目的是汇集广泛和互补的临床试验， 基本的调查专业知识，以促进执行小组的 科学议程。 哥伦比亚-ADARC单位可能拥有必要的元素 成功地进行了各种各样的致病性和 在人口统计学上多样化的人群中进行基于战略的临床试验。 本申请的具体目的是：（1）建立临床试验 有能力进行研究的单位， 艾滋病毒的发病机制和治疗。 具体而言，该单位将致力于 通过积极的协议积累，推进AACTG的研究议程 （2）在本集团的科学委员会的赞助下;（3）招募和保留 在AACTG试验中，不同人群的HIV感染者反映了 受影响的人口在曼哈顿，特别是北方曼哈顿，一个地区 这是一个受到艾滋病流行严重影响的国家， 这是流行病蔓延到市中心的典型代表。 这 将通过从大型初级保健机构招募患者来实现 基础和广泛的区域转介网络;及（3）促进本集团的 通过积极参与AACTG议定书和委员会来完成科学使命 哥伦比亚-ADARC调查人员。 这将包括分享新的 提高患者监测复杂性的技术， 在AACTG试验的背景下产生新的假设进行测试。 因此 哥伦比亚-ADARC ACTU将积极参与该小组的使命， 改善艾滋病毒感染者的健康，并制定治疗标准 艾滋病病毒感染。

DESCRIPTION (adapted from the application's abstract): The overall goal of this application is the formation of a clinical site within the Adult AIDS Clinical Trials Group (AACTG) which will effectively execute studies designed to improve the understanding and treatment of HIV disease. This site, a linkage of the Columbia Presbyterian Medical Center (Columbia) with the Aaron Diamond AIDS Research Center (ADARC) will be designated the Columbia-ADARC AIDS Clinical Trials Unit. Columbia will serve as the main unit and ADARC as the sub-unit in this collaboration of two institutions already scientifically linked by the recently awarded Center for AIDS Research (CFAR) grant. The intent is to bring together extensive and complementary clinical trials and basic investigative expertise to facilitate execution of the Group's scientific agenda. A Columbia-ADARC unit may possess the elements necessary to successfully carry out a diverse array of pathogenetically and strategically based clinical trials in a demographically diverse population. The specific aims of this application are: (1) to establish a clinical trials unit that has the capability to conduct studies which advance the knowledge of HIV pathogenesis and treatment. Specifically, this unit will be dedicated to further the AACTG's research agenda through active accrual to protocols sponsored by the scientific committees of the Group; (2) to recruit and retain a diverse population of HIV infected persons in AACTG trials who reflect the affected population in Manhattan, particularly Northern Manhattan, a region which has been severely affected by the HIV epidemic and one that is representative of the penetrance of the epidemic into the inner cities. This will be achieved through recruitment of patients from a large primary care base and broad regional referral network; and (3) to promote the Group's scientific mission by active participation in AACTG protocols and committees by Columbia-ADARC investigators. This will include sharing of new technologies that enhance the sophistication of patient monitoring and thereby generate new hypotheses to test in the context of AACTG trials. Thus, the Columbia-ADARC ACTU will be an active participant in the Group's mission to improve the health of HIV infected individuals and set standards for treatment of HIV disease.